Patent ID: 6017951
Filing Date: 2000-01-25
Classification: C07D

Abstract:
A method of treating congestive heart failure and myocardial infarction/myocardial ischemia comprising administering to a host suffering therefrom a therapeutically effective amount of a compound of formula I ##STR17## or a pharmaceutically acceptable salt thereof wherein: R.sub.1 is cycloalkyl substituted or unsubstituted of from 3 to 12 carbon atoms,phenyl substituted with from 1 to 5 substituents,naphthyl unsubstituted or substituted with from 1 to 5 substituents, orheteroaryl unsubstituted or substituted with from 1 to 5 substituents which heteroaryl has only oxygen as the heteroatom;R.sub.2 is alkyl substituted or unsubstituted straight, or branched, of from 1 to 12 carbon atoms,cycloalkyl substituted or unsubstituted of from 3 to 12 carbon atoms,aryl which is unsubstituted or substituted with from 1 to 5 substituents,heteroaryl which is unsubstituted or substituted with from 1to 5 substituents which heteroaryl has only oxygen as the heteroatom;R.sub.3 is alkyl substituted or unsubstituted straight, or branched, of from 1 to 12 carbon atoms,cycloalkyl substituted or unsubstituted of from 3 to 12 carbon atoms,aryl which is unsubstituted or substituted with from 1 to 5 substituents,heteroaryl which is unsubstituted or substituted with from 1 to 5 substituents which heteroaryl has only oxygen as the heteroatom;R4 is alkyl, unsubstituted or substituted with from 1 to 5 substituents;aryl unsubstituted or substituted with from 1 to 5 substituents;heteroaryl unsubstituted or substituted with from 1 to 5 substituents which heteroaryl has only oxygen as the heteroatom; andX is O or S with the proviso that (1-phenyl-ethyl)-carbamic acid-4-benzo[1,3]dioxol-5-yl-3-benzyl-2-(4-methoxy-phenyl)-5-oxo-2,5-dihyd ro-furan-2-yl ester is not included and furthermore, at least one of R1-R4 group represents a heteroaryl group in unit dosage form.